Balloon-occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma

• Published in: Kanzo Vol. 54; no. 1; pp. 81 - 83
• Main Authors: Toyoda, Mitsuo, Takizawa, Daichi, Arai, Hirotaka, Kobayashi, Takeshi, Takayama, Hisashi, Nagashima, Tamon, Abe, Takehiko
• Format: Journal Article
• Language: English; Japanese
• Published: The Japan Society of Hepatology 2013
• Subjects: balloon-occluded transcatheter arterial chemoembolization (B-TACE); hepatocellular carcinoma; miriplatin
• ISSN: 0451-4203; 1881-3593
• DOI: 10.2957/kanzo.54.81

The efficacy and safety of balloon-occluded transcatheter arterial chemoembolization (B-TACE) using miriplatin were investigated in 26 patients with hepatocellular carcinoma, and compared with conventional TACE (C-TACE). In the B-TACE group, a treatment effect (TE) of 4 was obtained in 61.5%, TE3 in 34.6%, TE2 in 3.8%, and TE1 in 0%. In the C-TACE group, the respective results were 44.2%, 34.6%, 19.2%, and 1.9%. Efficacy was significantly higher in the B-TACE group. There were no significant differences in the incidence of adverse events of grade 3 or more severe between the two groups. B-TACE using miriplatin is more useful than C-TACE, and B-TACE is as safe as C-TACE.